Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novelix PharmaceuticalsBOM:536565 +3.89%48 Net Debt Paydown Yield % is 0% as of Aug. 18, 2026. GuruFocus rates BOM:536565 with a GF Score™ of 48/100. The stock has 8 warning signs investors should review. Among 105 Medical Distribution companies, Novelix Pharmaceuticals ranks worse than 952380% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Novelix Pharmaceuticals's Net Debt Paydown Yield % was 0%.
Novelix Pharmaceuticals (BOM:536565) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Novelix Pharmaceuticals Net Debt Paydown Yield % Related Terms
Novelix Pharmaceuticals Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Novelix Pharmaceuticals's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelix Pharmaceuticals Net Debt Paydown Yield % Chart
BOM:536565 vs MCK, COR, CAH: Net Debt Paydown Yield % Comparison
For the Medical Distribution subindustry, Novelix Pharmaceuticals's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelix Pharmaceuticals Net Debt Paydown Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Novelix Pharmaceuticals's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Novelix Pharmaceuticals (BOM:536565) has a Net Debt Paydown Yield % of 0% as of Aug. 18, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Novelix Pharmaceuticals and its competitors. Over the past decade, Novelix Pharmaceuticals' Net Debt Paydown Yield % has ranged from 0.19 to 7.73. According to the industry distribution chart, Novelix Pharmaceuticals ranks #999999 out of 105 companies in the Medical Distribution industry.
Is Novelix Pharmaceuticals' Net Debt Paydown Yield % too high?
Novelix Pharmaceuticals' current Net Debt Paydown Yield % is 0%. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 7.73. Based on the distribution chart, Novelix Pharmaceuticals ranks #999999 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Novelix Pharmaceuticals has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' Net Debt Paydown Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #999999 out of 105 companies for Net Debt Paydown Yield %. This places Novelix Pharmaceuticals in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.10. Historically, Novelix Pharmaceuticals' own Net Debt Paydown Yield % has ranged from 0.19 to 7.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Distribution company?
The median Net Debt Paydown Yield % among Medical Distribution companies is 0.10, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Novelix Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Net Debt Paydown Yield % is 0.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current Net Debt Paydown Yield % is 0%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Novelix Pharmaceuticals (BOM:536565) has a current Net Debt Paydown Yield % of 0%. The current Net Debt Paydown Yield % is 0%. Novelix Pharmaceuticals' overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current Net Debt Paydown Yield % is 0% as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
48GF Score
Get the complete analysis for BOM:536565
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:536565 has been successfully added to your 
